Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
NCT ID: NCT02552849
Last Updated: 2017-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
305 participants
OBSERVATIONAL
2013-04-25
2017-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Overall study
Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
* Prescribed and/or currently taking Esbriet (pirfenidone) for the treatment of IPF
Exclusion Criteria
* Concomitant use of fluvoxamine
* Severe hepatic impairment or end-stage liver disease
* Severe renal impairment or end-stage renal disease requiring dialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Health Campus/Alberta Health Services/ University of Calgary
Calgary, Alberta, Canada
Edmonton Respiratory Consultants & Edmonton Sleep Lab
Edmonton, Alberta, Canada
Grey Nuns Community Hospital
Edmonton, Alberta, Canada
Synergy Respiratory Care
Sherwood Park, Alberta, Canada
Kelowna Respiratory and Allergy Cllinic
Kelowna, British Columbia, Canada
Mainra Rajesh R, Respirology
North Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
St. Paul's Hospital University of British Colambia Division of Hematology
Vancouver, British Columbia, Canada
Winnipeg Clinic
Winnipeg, Manitoba, Canada
Clinique de pneumologie de Moncton Respiratory Clinic
Moncton, New Brunswick, Canada
Dr. Graham W. Bishop Clinic
Saint John, New Brunswick, Canada
Professional Medical Corporation
St. John's, Newfoundland and Labrador, Canada
St. Clare'S Mercy Hospital
St. John's, Newfoundland and Labrador, Canada
Burlington Lung Clinic
Burlington, Ontario, Canada
Firestone Institute for Respiratory Health
Hamilton, Ontario, Canada
Hotel Dieu Hospital
Kingston, Ontario, Canada
Lawson Health Research Institute a joint venture of LHSC Research Inc and Lawson Research Institute
London, Ontario, Canada
Credit Valley Professional Building
Mississauga, Ontario, Canada
Oshawa Clinic
Oshawa, Ontario, Canada
Carling Respiratory Services
Ottawa, Ontario, Canada
Dr. Marc Newton Respirology
Owen Sound, Ontario, Canada
Toronto General Hospital; Investigational Pharmacy Services ENB - 217 (Pharmacy Receiving)
Toronto, Ontario, Canada
Dr. Syed Anees Medicine Profession Corporation
Windsor, Ontario, Canada
Dr Anil Dhar Professional Medicine Corporation
Windsor, Ontario, Canada
Hopital Notre-Dame
Montreal, Quebec, Canada
Clinique de pneumologie et du sommeil de Lanaudiere
Saint-Charles-Borromée, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML29808
Identifier Type: -
Identifier Source: org_study_id